UK researchers announced a breakthrough gene therapy that slowed Huntington's disease for the first time. Early-stage trials at University College London showed some patients’ condition progressed 75% slower over three years. The therapy, AMT-130, is delivered via direct brain injection.
Breakdown
- A new drug may slow Huntington's disease progression by up to 75%. 6s
- Patients could maintain independence and function for longer. 16s
- 29 trial participants received DNA injections into the brain and saw significant improvements after 36 months. 46s
- Unicure plans to apply for accelerated US market approval for the drug. 1m 29s